Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.

@article{Jiang2011AdjuvantIT,
  title={Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.},
  author={W Z Jiang and Guo-xian Guan and Hui-shan Lu and Ying-hong Yang and De-yong Kang and He-guang Huang},
  journal={Journal of surgical oncology},
  year={2011},
  volume={104 7},
  pages={760-4}
}
BACKGROUND The optimal duration of Imatinib adjuvant treatment for patients with high-risk gastrointestinal stromal tumors (GISTs) is uncertain. PATIENTS AND METHODS A total of 90 patients with high-risk GISTs after curative resection were recruited into this non-randomized case-control study, including 35 having Imatinib adjuvant therapy and 55 having follow-up alone. The recurrence-free survival (RFS) was compared. RESULTS After a median follow-up of 44.0 months, a significantly reduced… CONTINUE READING
8 Citations
22 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Members: NCCN Clinical Practice Guidelines in Oncology—Sarcoma

  • NCCN Sarcoma Pane
  • Fort Washington, PA: National Comprehensive…
  • 2010
1 Excerpt

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT

  • CD Blanke, GD Demetri, M von Mehren
  • J Clin Oncol 2008;26:620–625
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…